Head-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) and Valneva (NASDAQ:VALN)

GeoVax Labs (NASDAQ:GOVX – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Insider & Institutional Ownership

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

GeoVax Labs has a beta of 3.85, indicating that its share price is 285% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for GeoVax Labs and Valneva, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeoVax Labs 1 1 1 0 2.00
Valneva 2 0 1 0 1.67

GeoVax Labs currently has a consensus target price of $3,600.00, indicating a potential upside of 219,546.13%. Valneva has a consensus target price of $9.30, indicating a potential upside of 60.04%. Given GeoVax Labs’ stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than Valneva.

Earnings and Valuation

This table compares GeoVax Labs and Valneva”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GeoVax Labs $2.49 million 0.34 -$21.47 million ($11.34) -0.14
Valneva $142.94 million 3.87 -$130.33 million ($2.11) -2.75

GeoVax Labs has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeoVax Labs and Valneva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GeoVax Labs N/A -1,010.68% -420.06%
Valneva -110.33% -153.20% -39.50%

Summary

Valneva beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.

About Valneva

(Get Free Report)

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.